George Chao, MD
Endocrinology, Diabetes & Metabolism · Modesto, CANPI 1548204506
Payments from drug & device makers
Across 421 payments — averaging $44.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$4K
- AstraZeneca$3K
- Novo Nordisk$2K
- Boehringer Ingelheim$2K
- Amgen$2K
- Lilly USA, LLC$947
- plus $5K from 19 others
What the payments were for
- Consulting fees$4,36023%
- Food & beverage$14,03175%
- Education$2271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 8 | $3,844 |
| AstraZeneca | 50 | $3,077 |
| Novo Nordisk | 83 | $2,274 |
| Boehringer Ingelheim | 56 | $1,962 |
| Amgen | 38 | $1,559 |
| Lilly USA, LLC | 23 | $947 |
| Sanofi-aventis U.S. LLC | 37 | $853 |
| BETA Bionics, Inc. | 5 | $653 |
| Novartis | 7 | $520 |
| Johnson & Johnson | 17 | $458 |
| Esperion Therapeutics, Inc. | 41 | $417 |
| Abbott | 13 | $369 |
| Bayer | 5 | $325 |
| Ascendis Pharma Endocrinology Inc | 3 | $265 |
| Dexcom, Inc. | 3 | $218 |
| Astellas Pharma US Inc | 2 | $200 |
| Amarin Pharma, Inc. | 7 | $187 |
| Regeneron Healthcare Solutions, Inc. | 9 | $162 |
| Corcept Therapeutics | 1 | $118 |
| Tandem Diabetes Care, Inc. | 7 | $94 |
| GRT US Holding, Inc. | 2 | $48 |
| Insulet Corporation | 1 | $23 |
| Merck | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,618 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 783 | $1,232,158 |
| JardianceEmpagliflozin | 830 | $941,514 |
| FarxigaDapagliflozin Propanediol | 487 | $534,222 |
| MounjaroTirzepatide | 277 | $425,530 |
| RybelsusSemaglutide | 201 | $338,103 |
| Repatha SureclickEvolocumab | 311 | $259,967 |
| JanuviaSitagliptin Phosphate | 143 | $184,033 |
| TrulicityDulaglutide | 118 | $183,741 |
| Tresiba Flextouch U-100Insulin Degludec | 212 | $142,063 |
| Bydureon BciseExenatide Microspheres | 63 | $92,218 |
| VascepaIcosapent Ethyl | 126 | $89,246 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 73 | $84,333 |
| Praluent PenAlirocumab | 101 | $75,449 |
| KerendiaFinerenone | 48 | $67,377 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $64,992 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $2,274 | $1,586,737999 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $1,962 | $1,038,972905 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $947 | $626,398443 claims |
| AstraZenecaFarxiga | $3,077 | $534,222487 claims |
| MerckJanuvia | $17 | $184,033143 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $853 | $84,33373 claims |
| BayerKerendia | $325 | $67,37748 claims |
| Johnson & JohnsonInvokana | $458 | $23,26918 claims |
| Esperion Therapeutics, Inc.Nexlizet | $417 | $16,56917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Modesto
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
- Leila ChaychiSan Carlos$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.